← Eichor
Study identifier: NCT07532174 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efferon LPS Hemoadsorption in Cardiac Surgery Patients

Condition: Cardiac Disease · Multiple Organ Dysfunction Syndrome  ·  Sponsor: Efferon JSC

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoadsorption sessions: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.

This description comes directly from the study's public registry record.

Talk to the study team

Alexandr Shelehov-Kravchenko, PhD, MD  ·  +79636564765  ·  ais@efferon.ru

Always discuss trial participation with your own doctor first.

Locations (3)

Regional State Budgetary Healthcare Institution "Altai Regional Cardiological Dispensary"Barnaul, RussiaRecruiting
Almazov National Medical Research CentreSaint Petersburg, RussiaRecruiting
Pavlov First Saint Petersburg State Medical UniversitySaint Petersburg, RussiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07532174